Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Sesti, Giorgio ^a   Fiorentino, Teresa Vanessa ^a   Arturi, Franco ^a   Perticone, Maria ^a   Sciacqua, Angela ^a   Perticone, Francesco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; SOMATOMEDIN C; URIC ACID;

ADULT; AGED; ARTICLE; CARDIOMETABOLIC RISK; CAUCASIAN; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE; PROBABILITY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEX DIFFERENCE; SMOKING; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LINEAR MODELS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84895762885     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088569     Document Type: Article

References (47)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305.
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, et al. (2004) Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15:1307-1315. (Pubitemid 38526012)
3. Perticone F, Sciacqua A, Maio R, Perticone M, Laino I, et al. (2009) Renal function predicts cardiovascular outcomes in southern Italian postmenopausal women. Eur J Cardiovasc Prev Rehabil 16:481-486.
4. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, et al. (2004) Predictors of new-onset kidney disease in a community-based population. JAMA 291:844-850. (Pubitemid 38543772)
5. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, et al. (2004) The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140:167-174.
6. Sesti G, Succurro E, Arturi F, Andreozzi F, Laino I, et al. (2011) IGF-1 levels link estimated glomerular filtration rate to insulin resistance in obesity: A study in obese, but metabolically healthy, subjects and obese, insulin-resistant subjects. Nutr Metab Cardiovasc Dis 21:485-491.
7. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-95. (Pubitemid 39657013)
8. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231.
9. Petta S, Muratore C, Craxi A (2009) Nonalcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 41:615-25.
10. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134-140. (Pubitemid 34747534)
11. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, et al. (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:113-121. (Pubitemid 41002048)
12. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-873. (Pubitemid 46489550)
13. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, et al. (2009) Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7:234-238.
14. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850. (Pubitemid 33641605)
15. Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939-960.
16. Stepanova M, Younossi ZM (2012) Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10:646-50.
17. Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:1341-1350.
18. Perticone F, Maio R, Sciacqua A, Perticone M, Laino I, et al. (2009) Insulin-like growth factor-1 and glomerular filtration rate in hypertensive patients. J Hypertens 27:613-617.
19. Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A (2011) Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 34:757-66.
20. Arturi F, Succurro E, Procopio C, Pedace E, Mannino GC, et al. (2011) Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 96: E1640-E1644.
21. Hribal ML, Procopio T, Petta S, Sciacqua A, Grimaudo S, et al. (2013) Insulin-Like Growth Factor-1, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 98:E304-E308.
22. Sciacqua A, Perticone M, Miceli S, Laino I, Tassone EJ, et al. (2011) Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. Nutr Metab Cardiovasc Dis 21:485-491.
23. Perticone F, Maio R, Perticone M, Sciacqua A, Shehaj E, et al. (2010) Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 122:379-384.
24. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, et al. (2009) Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 35:277-287.
25. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, et al. (2008) The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis 51:212-223.
26. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E (2011) Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 54:1020-9.
27. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, et al. (2008) Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51:444-450.
28. Targher G, Chonchol M, Bertolini L, Rodella S, Lippi G, et al. (2010) Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 5:2166-2171.
29. Yasui K, Sumida Y, Mori Y, Mitsuyoshi H, Minami M, et al. (2011) Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 60:735-9.
30. Chang Y, Ryu S, Sung E, Woo HY, Oh E, et al. (2008) Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 57:569-576. (Pubitemid 351320606)
31. Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, et al. (2008) Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 19:1564-1570.
32. Myers RP, Fong A, Shaheen AA (2008) Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 28:705-12. (Pubitemid 351541104)
33. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, et al. (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38:518-26. (Pubitemid 36919874)
34. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846-854. (Pubitemid 46631552)
35. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317-1325. (Pubitemid 43980111)
36. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA (2008) Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57:1441-1447.
37. Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, et al. (2013) NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One 8:e58360.
38. Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD (2013) NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 19:1219-29.
39. Kim D, Kim WR, Kim HJ, Therneau TM (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57:1357-65.
40. Succurro E, Arturi F, Grembiale A, Iorio F, Fiorentino TV, et al. (2011) One-hour post-load plasma glucose levels are associated with elevated liver enzymes. Nutr Metab Cardiovasc Dis 21:713-718.
41. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2013) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167.
42. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419. (Pubitemid 15018832)
43. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604-612.
44. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation120:1640-1645.
45. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS (1994) Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 45:598-604. (Pubitemid 24065099)
46. Haylor J, Singh I, el Nahas AM (1991) Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int 39:333-335.
47. Giordano M, DeFronzo RA (1995) Acute effect of human recombinant insulin-like growth factor I on renal function in humans. Nephron 71:10-15.